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Clinical and laboratory data on severe acute respirato-
ry syndrome (SARS), particularly on the temporal progres-
sion of abnormal laboratory findings, are limited. We
conducted a prospective study on the clinical, radiologic,
and hematologic findings of SARS patients with pneumo-
nia, who were admitted to National Taiwan University
Hospital from March 8 to June 15, 2003. Fever was the
most frequent initial symptom, followed by cough, myalgia,
dyspnea, and diarrhea. Twenty-four patients had various
underlying diseases. Most patients had elevated C-reactive
protein (CRP) levels and lymphopenia. Other common
abnormal laboratory findings included leukopenia, throm-
bocytopenia, and elevated levels of aminotransferase, lac-
tate dehydrogenase, and creatine kinase. These clinical
and laboratory findings were exacerbated in most patients
during the second week of disease. The overall case-fatal-
ity rate was 19.7%. By multivariate analysis, underlying dis-
ease and initial CRP level were predictive of death. 
S
evere acute respiratory syndrome (SARS) is a new
infectious disease, first recognized in November 2002
(1). SARS has spread rapidly around the world: >8,400
cases have been reported from 30 countries on five conti-
nents (2,3).
Previous reports have described some major clinical
findings of SARS, including the temporal progression of
clinical symptoms and chest radiography, the outcomes,
suggested treatment protocol, and risk factors for death
(4,5). However, data are still limited on the temporal pro-
gression of abnormal laboratory findings, such as leukope-
nia, lymphopenia, thrombocytopenia, elevated lactate
dehydrogenase (LDH), elevated aspartate aminotrans-
ferase (AST), elevated alanine aminotransferase (ALT),
elevated creatine kinase (CK), and elevated C-reactive
protein (CRP) and the roles each of these plays in predict-
ing outcomes and complications. Although So et al. have
suggested a treatment protocol with the emphasis on early
use of high-dose steroids (6), whether this treatment is bet-
ter than others is unclear. 
We conducted a prospective study on the clinical, radi-
ologic, and hematologic findings of SARS patients with
pneumonia, who were admitted to National Taiwan
University Hospital (NTUH) from March 8 to June 15,
2003. Most of these patients were treated following a stan-
dard treatment protocol, different from that suggested by
the study group in Hong Kong (6). We report on the clini-
cal features of our SARS patients with pneumonia, with
emphasis on temporal progression of laboratory findings,
treatment outcome, and risk factors for poor prognosis.
Methods
Setting 
NTUH is a 2000-bed, university-affiliated medical cen-
ter located in northern Taiwan. The center provides both
tertiary and primary care for patients. It was also the pri-
mary hospital caring for SARS patients during the SARS
outbreak in Taiwan.
Patient Description and Treatment Protocol
All patients who fulfilled the revised World Health
Organization (WHO) definition of probable SARS (7) in
whom pneumonia developed and who received treatment
at NTUH during March 8 to June 15, 2003, were enrolled
in this study. Except for the first patient, who did not
receive any of the following treatments, and the second,
third, and fourth patients, who received steroid in the first
week of their disease, all patients received treatments that
conformed to the guideline described here. Oral ribavirin
was prescribed soon after the diagnosis of SARS was
made; the loading dose was 2,000 mg followed by 1,200
mg per day if the body weight was >75 kg, or 1,000 mg per
day if the body weight was <75 kg. This treatment lasted
10 days unless adverse effects developed. Antimicrobial
agents for community-acquired pneumonia, either moxi-
floxacin alone or ceftriaxone plus azithromycin, were
administered at the same time. Methylprednisolone was
usually administered in the second week of the disease if
any of the following occurred: a flare of fever, progression
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or resurge of CRPlevel, or rapid deterioration of chest radi-
ographic findings (development of new infiltration).
Methylprednisolone was indicated in the first week of dis-
ease only if clinical symptoms or laboratory abnormalities
(such as elevated CK, LDH, CRP) worsened rapidly, and
rapidly progressed abnormalities were found on chest radi-
ograph. The dosage was 2 mg/kg/day for 5 days, and then
it was tapered off. Pulse therapy with methylprednisolone,
500 mg/day for 3 days, was used if there was major disease
progress under the standard regimen. Intravenous
immunoglobulin (IVIG) was administered if severe
leukopenia (<2 x 109/L), thrombocytopenia (<100 x 109/L),
or both occurred, or if lesions on chest radiography pro-
gressed rapidly in the first week of disease. The dosage of
IVIG was 1 g/kg/day for 2 days. Once patients were intu-
bated and supported by a mechanical ventilator, respirato-
ry care followed the principles suggested for managing
acute respiratory distress syndrome (8).
Laboratory Examination 
The etiologic workup included the sputum Gram stain
and acid-fast stain, sputum culture for bacteria, sputum
chlamydial antigen, throat swab for virus isolation, urine
pneumococcal antigen, and urine legionella antigen. We
tested antibody reactions of both acute- and convalescent-
phase serum specimens, 4 weeks apart, for Mycoplasma,
Chlamydia  influenza virus, parainfluenza virus, aden-
ovirus, coxsackievirus, respiratory syncytial virus, and
SARS-related coronavirus (SARS-CoV). We also took
throat swabs for reverse transcription–polymerase chain
reaction (RT-PCR) for SARS-CoV. The other routine labo-
ratory tests, such as the hemogram, serum AST, ALT, CK,
LDH, and CRP level, were examined every other day dur-
ing hospitalization. A chest radiography was also per-
formed every other day during hospitalization.
Infection Control Measures
Once a patient was diagnosed as having SARS, he or
she was sent to a negative-pressure ventilated room imme-
diately. No visitor or family member was allowed to enter
this room. All healthcare workers caring for SARS patients
were asked to adhere strictly to contact and airborne pre-
cautions. Before entering isolation rooms to care for SARS
patients, all healthcare workers washed their hands and put
on personal protective equipment, including gowns,
gloves, N95 respirators, goggles, and face shields. After
caring for SARS patients, such workers were to take off
the personal protective equipment in the anteroom and
wash their hands before leaving the isolation room. The
health of healthcare workers who had any contact with
SARS patients or their environments was monitored daily
for 14 days after the last exposure. Once fever developed
in a worker, he or she was immediately hospitalized and
placed in isolation in a specially designated ward.
Data Collection 
A standard case report form modified from one
designed by the Centers for Disease Control and
Prevention for SARS was used to collect demographic and
clinical data (9).Severity of underlying disease was classi-
fied by using the modified risk stratification proposed by
McCabe: rapidly fatal (death expected within 1 year), ulti-
mately fatal (death expected within 5 years), or nonfatal
(death expected >5 years or no underlying disease) (10).
Statistics
All statistical analysis was performed with SPSS ver-
sion 10.0 (SPSS, Chicago, IL). Logistic regression was
used for univariate and multivariate analysis. Continuous
variables were compared with the t test. Categorical vari-
ables were compared by using the Fisher exact test. A p
value < 0.05 was considered significant.
Results 
During the study period, 76 patients were enrolled.
Their demographic and clinical data are detailed in
Table 1. The male-to-female ratio was 34:42. Their age
was 24–87 years (median 46.5 years). Twenty-four
patients had various underlying diseases, including cardio-
vascular disorders in 13 patients, diabetes mellitus in 10,
hepatobiliary disorders in 6, history of cerebrovascular
accidents in 3, chronic renal diseases in 2, pulmonary
fibrosis in 1, history of intravenous drug abuse in 1, and
adrenal insufficiency in 1. Fourteen of these 24 patients
had underlying diseases classified as rapidly fatal (diabetes
mellitus, ischemic heart disease, plus congestive heart fail-
ure in four patients; diabetes mellitus, ischemic heart dis-
ease, plus cerebrovascular accident with being bedridden
in three; diabetes mellitus, ischemic heart disease, plus
end-stage renal disease in two; diabetes mellitus plus
decompensated liver cirrhosis in one; and ischemic heart
disease plus massive ischemic bowel in one) or ultimately
fatal (severe pulmonary fibrosis in one, ischemic heart dis-
ease in two). Most frequent initial symptoms were fever,
cough, myalgia, dyspnea, diarrhea, and rigor. Three of the
24 patients who had diarrhea had previously received var-
ious antimicrobial agents. The duration from symptom
onset to a patient’s visiting NTUH was 1–12 days (median
3 days). The initial laboratory data are detailed in Table 2.
Abnormalities on chest radiography suggesting pneumonia
were found in 56 of the 76 patients. Lesions were found in
one lobe in 33 patients, two lobes in 15 patients, three
lobes in 4 patients, four lobes in 2 patients, and five lobes
in 2 patients. Abnormalities visible on chest radiography
developed in the other 20 patients after admission. The
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on the chest radiography were first noted was 1–12 days
(median 4 days).
During hospitalization, 69 patients (90.8%) had respira-
tory distress and needed oxygen supplements. The dura-
tion from disease onset to severe respiratory distress was a
mean of 9.8 ± 3.0 days (standard deviation [SD]).
Endotracheal intubation with ventilator support was indi-
cated for 26 patients, but 3 patients refused intubation.
Among the 23 intubated patients, the duration from disease
onset to intubation was 8.4 ± 3.3 (SD) days. Eight of these
23 patients were successfully extubated 12.1 ± 6.1 (SD)
days later. Twelve of the 23 patients died, and 3 patients
remained intubated at the end of the study because of
marked lung fibrosis. 
Thirty-one patients (40.8%) experienced exacerbation
of diarrhea after admission. All had received various
antimicrobial agents since hospitalization. The duration
from disease onset to severe diarrhea was 8.9 ± 4.7 (SD)
days. 
During the disease course, leukopenia, lymphopenia,
and thrombocytopenia were found in 40, 72, and 61
patients, respectively. Elevation of AST and ALT was noted
in 66 and 59 patients, respectively. Elevation of serum
LDH, CK, and CRP levels was found in 73, 34, and 71
patients, respectively. The laboratory values of the various
parameters listed above typically peaked in severity in the
second week of illness (Table 3). The Figure demonstrates
the relationships between the time points when several clin-
ical and laboratory parameters became most severe.
New lesions visible on chest radiography developed in
64 patients during hospitalization, including new lesions
limited to one lung lobe in 21 patients, two lobes in 13,
three lobes in 16, four lobes in 7, and five lobes in 7. The
duration from disease onset to the most severe chest radi-
ography findings was 9.6 ± 2.9 (SD) days. 
Sputum Gram stain and acid-fast stain, sputum culture
for bacteria, sputum chlamydial antigen, throat swab for
virus isolation, and urine legionella and pneumococcal
antigen tests were available for all 76 patients; all results
were negative. Paired serum specimens were available for
41 patients. Tests for antibody reaction to Mycoplasma,
Chlamydia,  influenza virus, parainfluenza virus, aden-
ovirus, coxsackievirus, and respiratory syncytial virus
were negative. Of these 41 patients, immunoglobulin (Ig)
G antibody to SARS-CoV was detected by immunofluo-
rescent assay in 38 patients (92.7%). Twenty-six (34.2%)
of the total 76 patients had positive results on throat swab
RT-PCR for SARS-CoV. Among the 50 patients whose
throat swab results were negative for SARS-CoV by RT-
PCR, 28 seroconverted to SARS-CoV. The other 22
patients, who had no direct microbiology or serologic evi-
dence for SARS-CoVinfection at the time the study ended,
had clinical courses compatible with those of probable
SARS and clear relationships as well as exposures to the
initial immigrant clusters and the later intrahospital out-
breaks in Taiwan (11). Their diagnoses of SARS had also
been confirmed by a committee of the Center for Disease
Control (Taiwan). 
The first patient did not receive any treatment specific
for SARS. Five patients did not receive ribavirin treatment
because its use was contraindicated for them because of
conditions such as cardiac arrhythmia and cardiomyopa-
thy. Seven patients did not receive steroids because their
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Table 1. Demographic data and initial clinical signs and symptoms
of 76 patients with probable SARS
a 
Data  No. of cases (%) 
Sex   
Male  34 (44.7) 
Female  42 (55.3) 
Age (y) (range, median)  24–87 (46.5)   
Underlying disease (no.)   
Nonfatal  62 (81.6) 
No underlying disease  52 (68.4) 
Mild underlying disease  10 (13.2) 
Ultimately fatal  3 (3.9) 
Rapidly fatal  11 (14.5) 
Initial symptoms   
Fever  76 (100) 
Cough  47 (61.8) 
Myalgia  37 (48.7) 
Dyspnea  31 (40.8) 
Diarrhea  24 (31.6) 
Rigor  23 (30.3) 
Headache  14 (18.4) 
Nausea  9 (11.8) 
Sore throat  7 (9.2) 
Vomiting  3 (3.9) 
Rhinorrhea  2 (2.6) 
aSARS, severe acute respiratory syndrome. 
 
Table 2. Initial laboratory data of 76 patients with SARS
a 
Laboratory parameters 
(normal range) 
Mean ± standard 
deviation 
No. (%) of 
patients with 
abnormal data 
Leukocyte counts (4–9 x 10
9/L)  6.0 ± 2.9   
Leukopenia    15 (19.7) 
Lymphopenia
b     49 (64.5) 
Platelet counts (150–450 X 0
9/L)  159.7 ± 54.0   
Thrombocytopenia      35 (46.1) 
AST (<35 U/L)  36.7 ± 20.0  24
c (35.3) 
ALT (<35 U/L)  27.5 ± 20.4  11
d (23.9) 
LDH (<460 U/L)  597.8 ± 426.0  9
e (56.3) 
CK (<190 U/L)  216.5 ± 444.3  17
f (26.1) 
CRP (<0.8 mg/dL)  3.9 ± 3.6  53
g (77.9) 
aSARS, severe acute respiratory syndrome; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; LDH, lactate dehydrogenase; CK, creatine kinase; CRP, 
C-reactive protein. 
bDefined as <1 x 10
9/L. 
cOnly 68 patients had been tested. 
dOnly 46 patients had been tested.
   
eOnly 16 patients had been tested. 
fOnly 65 patients had been tested. 
gOnly 68 patients had been tested. cases were rapidly fatal after diagnosis. These seven
patients died mainly because of their underlying diseases,
especially cardiac events. Their SARS cases did not
progress to the point that steroids were indicated according
to our treatment protocol. 
Eight patients received pulse steroid therapy for pro-
gressive clinical conditions, with the usual dosage of
steroids. Forty patients received IVIG infusion for severe
cytopenia (thrombocytopenia, leukopenia, or both) (22
patients in total) or marked local progression of pulmonary
lesions on chest radiography in the first week of disease
(18 patients). Those 22 patients who received IVIG for
severe cytopenia did not receive steroids while on IVIG;
their leukocyte counts were 2.6 ± 1.2 x 109/L and 4.3 ± 2.8
x 109/L, before and after the use of IVIG, respectively (p =
0.014, by paired t test). Their platelet counts were 104 ± 35
x 109/L and 141 ± 46 x 109/L, before and after IVIG,
respectively (p = 0.002, by paired t test). 
Various complications developed in 18 patients during
hospitalizations, including rhabdomyolysis, peripheral
neuropathy, acute renal failure, and fungal or bacterial
superinfection (Table 4). Among the 18 nosocomial infec-
tions, 6 were bloodstream infections; 3 of these were
caused by enterococci, 2 by methicillin-resistant
Staphylococcus epidermidis, and 1 by methicillin-resistant
S. aureus. Eleven episodes were lower respiratory infec-
tions, diagnosed by the existence of new infiltration on
chest radiography, purulent sputum, phagocytosis of bacte-
ria by neutrophils in sputum (indicated by sputum Gram
stain), positive sputum culture for bacteria, and response to
effective antimicrobial agents. The last episode was a
catheter-related infection caused by Candida parapsilosis. 
The overall death rate was 19.7% (15/76). Among the
14 patients whose underlying diseases were classified as
ultimately fatal or rapidly fatal, the rate of death was
78.6% (11/14). For the other 62 patients with mild under-
lying diseases or without underlying disease, the death rate
was 6.5% (4/62). The time from disease onset to death in
these 15 patients was 4–42 days (median 12 days). For the
26 patients whose clinical conditions indicated endotra-
cheal intubation with ventilator support, the rate of death
was 57.7% (15/26). When we used the logistic regression
model for univariate analysis, age, underlying disease
(nonfatal versus ultimately or rapidly fatal), initial CRP
level, initial absolute neutrophil count (ANC), peak CK
level, and peak CRP level were predictors of death. Age,
sex, underlying disease, initial chest radiographic findings,
initial CRP level, initial ANC, peak CK level, lowest lym-
phocyte count, worst chest radiographic findings, peak
LDH level, and peak CRP level were the predictive factors
for respiratory failure (Table 5). However, when we used
logistic regression for multivariate analysis, underlying
disease and initial CRPlevel were the only two factors sig-
nificantly predictive for death (odds ratio [OR], 83.333 and
1.447 every 1 mg/dL increase, respectively; p < 0.001 and
p = 0.006, respectively), and age, initial CRP level, and
worst chest radiographic findings were predictive for res-
piratory failure (OR 1.076, 1.419 every 1 mg/dL, and
2.501 every one-lobe involvement, respectively; p = 0.01,
p = 0.01, and p = 0.006, respectively). For the 65 patients
who received steroids as the treatment protocol described
above, 3 remained febrile and needed further pulse steroid
therapy after the use of methylprednisolone with the
dosage of 2 mg/kg/day. For the other 62 patients who
became afebrile after steroid was administered, 12 had
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Table 3. Data on most severe abnormal laboratory parameters of 76 SARS patients during their disease course
a 
Laboratory parameters (no. of patients, %)  Mean ± SD of most severe data (unit)  Duration from disease onset to most severe data noted 
Leukopenia (40, 52.6)  2.5 ± 0.7 (x 10
9/L)  7.5 ± 2.4 days 
Lymphopenia (72, 94.7)  0.6 ± 0.3 (x 10
9/L)  7.0 ± 2.5 days 
Thrombocytopenia (61, 80.3)  102.3 ± 31.3 (x 10
9/L)  6.9 ± 2.0 days 
Elevated AST (66, 86.9)  142.0 ± 323.6 (U/L)  10.3 ± 4.6 days 
Elevated ALT (59, 77.6)  103.7 ± 132.2 (U/L)  13.3 ± 5.0 days 
Elevated LDH (73, 96.1)  1,323.8 ± 1,487.2 (U/L)  10.8 ± 3.9 days 
Elevated CK (34, 44.7)  12,165.7 ± 58,226.9 (U/L)  7.8 ± 4.2 days 
Elevated CRP (71, 93.4)  7.1 ± 4.0 (mg/dL)  8.5 ± 3.0 days 
aSARS, severe acute respiratory syndrome; SD, standard deviation; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CK, 
creatine kinase; CRP, C-reactive protein. 
Table 4. Complications found in 76 SARS patients
a 
Complication  No. of patients (%) 
Rhabdomyolysis  4 (5.3) 
Peripheral neuropathy  5 (6.6) 
Acute renal failure  3 (3.9) 
Gastrointestinal bleeding  2 (2.6) 
Acute myocardial infarction  1 (1.3) 
Bacteria superinfection  10 (13.2) 
Candida parapsilosis superinfection  1 (1.3) 
MRSA  4 (5.3) 
MRSE  2 (2.6) 
Enterococci  3 (3.9) 
Acinetobacter baumannii  3 (3.9) 
Klebsiella pneumoniae  2 (2.6) 
Enterobacter cloacae  1 (1.3) 
Serratia marcescens  1 (1.3) 
Total  18 (23.7) 
aSARS, severe acute respiratory syndrome; MRSA, methicillin-resistant 
Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis. 
Some patients experience more than one complication. rebound of fever 2–3 days after the temporary deferves-
cence. Seven of the 12 patients became afebrile again and
had no fever 1–2 days after the transient rebound of fever
without specific intervention. The other five patients
received further pulse steroid therapy to control the fever
and exacerbated clinical symptoms. For those 62 patients
alive at the end of this study, the time to defervescence
after disease onset was 10.3 ± 5.1 days. Major lung fibro-
sis directly caused by SARS developed in 6 of these 62
patients; this condition resulted in exertional dyspnea in 2
patients, oxygen-supplement dependence in 1 patient, and
respiratory failure in 3 patients. By the end of the study, 58
of the 62 patients had been successfully discharged from
NTUH. The other four patients, including three patients
who had respiratory failure and one who was dependent on
oxygen supplement, remained hospitalized. The duration
of follow-up for these four patients was >4 weeks. 
Discussion
Our study of 76 patients with probable SARS with
pneumonia demonstrated a high case-fatality rate (19.7%),
especially in patients with major underlying diseases and
high initial CRP levels. Those patients who needed endo-
tracheal intubation with ventilator support during their
hospitalization also had a high rate of death (57.7%).
Various complications developed in a high proportion of
patients (23.7%) during their disease. 
The yield rate of RT-PCR assay for SARS-CoV was
lower (34.2%) than in a previous report (5). This finding
might be because only throat swabs, not nasopharyngeal
aspirations or stools, were obtained for RT-PCR in the
present study.
As in previous reports from other areas (4,5), fever was
the most frequent initial symptom in our cases. Compared
to those previous reports, more patients in our case series
initially had diarrhea (31.6% vs. 1%–19.6%). Therefore,
according to our observations, diarrhea may be also con-
sidered as an early symptom and clue for SARS. In addi-
tion, 18 patients had initial symptoms of diarrhea when
fever occurred. Gastrointestinal tract should be considered
as another important primary infection site of SARS-CoV. 
A previous study reported the temporal progression of
clinical and radiologic findings in SARS patients and indi-
cated that several parameters would become more severe in
the second and third week of disease (5). Our study had
similar findings. Although the exacerbation of diarrhea
might be due to the use of antimicrobial agents, the diarrhea
improved subsequently without their change or discontinu-
ation. Therefore, exacerbation of diarrhea is more likely
due to SARS itself. Our study also demonstrates that most
patients’ abnormal laboratory findings may become more
severe in the second week of disease (Table 3 and Figure). 
Our treatment protocol was somewhat different from
that suggested by So et al. (6). The timing of steroids was
modified according to our experiences in treating the sec-
ond, third, and fourth patients, whose exacerbation of oxy-
gen demand and chest radiography lesions were not
prevented by early steroid use. Moreover, steroids are
immunosuppressive. A previous study pointed out that the
viral load of SARS Co-V in SARS patients arrived at peak
levels at approximately day 10 of disease (5). Steroids
were used as an adjunctive therapy for infectious diseases
to reduce the severity of inflammatory damage that could
occur in the later stage of disease (12). Using steroids was
also a risk factor for subsequent nosocomial infection (13).
For all these reasons, we delayed the use of steroids.
Among the 65 patients who received steroids as the treat-
ment protocol, 15 (23.1%) had rebound or persistence of
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Table 5. Univariate analysis of factors predictive for death and respiratory failure (logistic regression)  
Odds ratio  p value 
Factors  Mortality  ResF  Mortality  ResF 
Age (every 1 y)
b  1.093  1.082  <0.001  <0.001 
Sex (male to female)  3.086  2.841  0.064  0.036 
Severe underlying disease
c   3.973  3.023  <0.001  <0.001 
Initial CRP level
b,c (every 1 mg/dL)  1.300  1.391  0.004  <0.001 
Initial ANC count (every 0.1 x 10
9/L)  1.022  1.031  0.020  0.006 
Initial lymphocyte count (every 0.1 x 10
9/L)  0.091  0.916  0.188  0.162 
Initial platelet count (every 100 x 10
9/L)  0.668  0.565  0.485  0.248 
Initial CXR findings (every one-lobe involvement)  1.482  1.941  0.154  0.025 
Peak CRP level (every 1 mg/dL)  1.193  1.385  0.033  <0.001 
Lowest lymphocyte count (every 0.1 x 10
9/L)  0.801  0.804  0.079  0.032 
Peak LDH level (every 100 U/L)  1.132  1.160  0.124  0.008 
Peak CK level (every 1 U/L)  1.093  1.082  <0.001  <0.001 
Lowest platelet count (every 100 x 10
9/L)  0.724  0.541  0.608  0.261 
Worst CXR findings (every one-lobe involvement)  1.505  2.147  0.064  <0.001 
aResF, respiratory failure; CRP, C-reactive protein; ANC, absolute neutrophil count; CXR, chest radiography; LDH, lactate dehydrogenase; CK, creatine kinase.   
bFactors that remained statistically significant after multivariate analysis for respiratory failure. 
cFactors that remained statistically significant after multivariate analysis for death. fever after initial steroid use. This fever rebound is less fre-
quent than in prior reports (43.3%–85.3%) (5,6). However,
the overall death rate in our study was similar to that
reported from Hong Kong (7%–20.9%) (3,5). Comparing
the treatment results of our study and previous ones is dif-
ficult because of different case definitions, patient back-
grounds, and disease severity, as well as obscure
descriptions about complications in SARS patients in pre-
vious reports. All our patients had severe cases. Therefore,
the best timing of starting steroid usage and the total dura-
tion of steroid usage in SARS patients to improve treat-
ment outcome remain unclear and need further study. 
Hemophagocytotic syndrome was documented in our
second patient by bone marrow biopsy (14). Her initial
clinical signs and symptoms included fever, severe
leukopenia, and thrombocytopenia. Her hemophagocytotic
syndrome was relieved after using IVIG. This treatment
was suggested because of its immune modulating effect
(15). The other 21 patients in whom severe leukopenia or
thrombocytopenia developed in the first week of disease
also received IVIG therapy empirically. IVIG appeared
effective for controlling leukopenia and thrombocytope-
nia: after infusion, the patients’ leukocyte and platelet
counts increased to a significantly higher level (p = 0.002).
The increase of leukocyte and platelet counts might have
prevented some further complications directly resulting
from severe leukopenia and thrombocytopenia, such as
infection and tendency to bleed. Although we had no con-
trol group, we believe that IVIG may play a role in treat-
ing selected SARS patients. 
Advanced age, co-existing conditions, high peak LDH
level, and high initial ANC count had been reported as fac-
tors that predict poor prognosis for SARS patients (4,5,16).
By univariate analysis, many parameters predicted death
or respiratory failure (Table 3). However, by using the
logistic regression model for multivariate analysis, severe
underlying disease and high initial CRP level were the
only two factors that predicted death; age, initial CRP
level, and worst chest radiographic findings predicted res-
piratory failure. The role of CRPin predicting the outcome
of SARS patients has not been discussed in previous stud-
ies (4,5,16). The discovery of CRP was reported in 1930
by Tillet and Francis (17). CRP parallels the severity of
inflammation or tissue injury and is a useful marker for
disease, response to therapy, and ultimate recovery
(18,19). Although initial CRP level was not available in
eight patients in this cohort, our findings suggest that CRP
also parallels well with the severity and outcome of SARS
patients. Age and underlying disease were strongly corre-
lated: all our patients with severe underlying disease were
older (age >65 years). In a statistical model, these two fac-
tors might interfere with each other and lead to the conclu-
sion that age, not underlying disease, was an independent
risk for respiratory failure; however, the opposite was true.
The worst chest radiographic finding outlined the most
severe extent of impaired lung function. This finding
might explain why it was an independent factor for respi-
ratory failure. However, other conditions unrelated to pul-
monary condition, such as underlying disease or
complications during hospitalization, contributed to death.
These findings might explain why worst chest radiograph-
ic finding was not an independent factor for death. 
Forty-two patients in this cohort were admitted to
NTUH through the emergency department, which has no
facility to check serum LDH level. Also, during intrahos-
pital SARS outbreaks (11), heavy clinical loads and fre-
quent bed transfers made it difficult for the primary care
physician to collect laboratory data as the schedule
described above. Therefore, initial serum LDH level and
CRP level were available for only 16 and 68 patients,
respectively; thus, initial LDH level could not be factored
into our analyses. Since both CRPand LDH are markers of
inflammation, whether the initial LDH level is also an
independent risk factor for death or respiratory failure
needs further study.
Complications during the disease courses of SARS
patients have been seldom or obscurely discussed previ-
ously (4,5,16). Acute renal failure, which might be more
likely caused by methicillin-resistant S. aureus infection
and rhabdomyolysis, was found in three patients. Acute
myocardial infarction occurred in a patient who had been
diagnosed with long-standing coronary artery disease.
Gastronintestinal bleeding, which might be due to critical
illness, occurred in two patients. Rhabdomyolysis has been
reported to be associated with viral infection (20,21). Our
observation suggests that SARS Co-V infection might also
be associated with this complication (22). Although
peripheral neuropathy had also been reported with viral
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Figure. The time relationships between the time points of deferves-
cence, initiation of steroid, and when chest radiographic finding as
well as various laboratory parameters became most severe. Mean
and standard deviation (days) are presented. CXR, chest radiog-
raphy; ALT, alanine aminotransferase; LDH, lactate dehydroge-
nase; AST, aspartate aminotransferase; CRP, C-reactive protein;
CK, creatine kinase. infection (23), neuropathy caused by steroids or acute
illness should also be considered contributing causes in our
four patients with neuropathy (24,25).
Eleven patients had bacterial or fungal superinfection
during hospitalization. All nosocomial infections occurred
while patients were intubated and supported with a
mechanical ventilator (p < 0.001 by Fisher exact test). The
nosocomial infection rate among SARS patients was 237
per 1,000 discharges, which was much higher than that of
all patients at NTUH (49 per 1,000 discharges) (26).
Steroid use and more severe clinical conditions than usual
patients, such as higher rate of respiratory failure, might be
the reasons. 
Our study shows that SARS has an overall complica-
tion rate of 23.7% and case-fatality rate of 19.7%. Clinical
symptoms and abnormal radiographic and laboratory find-
ings might become most severe in the second week of dis-
ease. In addition to ribavirin and steroids, IVIG may play
a role in treating selected patients. Underlying disease and
initial CRP level were the two independent predictors of
death; age, initial CRP level, and worst chest radiographic
finding were the three independent factors predicting res-
piratory failure for adult SARS patients. 
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